International Biotechnol... Share Discussion Threads

[philo124] 12/2/2013 14:43

NAV c248p.

[davebowler] 29/1/2013 12:56

Date NAV Pence
Monday 28 Jan Ex Income 251.45

[philo124] 21/1/2013 18:51

Yep, agreed sit it with a chunky of GSK to balance yield.

[127tolmers] 21/1/2013 17:15

one for my Sipp, ticks the boxes, performance, discount and prepared to ignore the yield

[davebowler] 17/1/2013 13:46

BIOG is at a 1% premium whereas IBT (similar) is at a 16% discount.

[philo124] 13/12/2012 16:52

Bought for SIPP; already hold BIOG & PCGH.

[davebowler] 26/11/2012 14:42

Ridiculously cheap at 17% discount to NAV compared to similar BIOG at 5% discount.

[gilston] 23/11/2012 16:55

Why the recent decline in the s.p.? Profit taking?

[127tolmers] 19/10/2012 14:22

Good results today persuaded me to buy. A few key bits.


"Investment Performance

In this, my first letter to shareholders as Chairman, I am pleased to report to you a substantial positive return for the year ended 31 August 2012. The NAV increased by 41.9% to 232.5p per share. With a small narrowing of the discount to 12.0% from 12.7%, the Company's share price increased by 43.0%. By comparison, the FTSE All-Share Index produced a total return of just 10.2% over the same period.

For the first time in several years, positive absolute performance was generated from both the quoted and unquoted parts of the portfolio, with a 47.8% and 21.7% increase for each, respectively. Investor enthusiasm for the biotechnology sector improved dramatically over the period against the backdrop of positive, yet muted, price gains for the broader stock market.

With the Company's share price currently trading at a 12.0% discount to NAV, and the unquoted portfolio comprising 16.0% of overall NAV, the market is assigning little value to the unquoted portfolio. The Board believes this represents a valuation anomaly and offers investors an excellent opportunity to become Shareholders in the biotechnology industry's quiet revolution, even after the quoted sector's recent very strong run.

The Company currently recognises GBP0.7m of fair value for future milestone payments potentially due to the Company from unquoted investments already exited. The receipt of these payments is contingent on pre-agreed, and legally-binding, operational or clinical development milestones being achieved. If paid in full, these milestone payments would amount to GBP9.6m on current exchange rates, representing GBP8.8m of additional unrecognised value."

[davebowler] 27/9/2012 11:54

Bullish outlook;

[davebowler] 27/9/2012 11:53

I stand corrected -I only looked at the last 5 years!Presumably they peaked in the 'Tech' bubble.

[gallops] 25/9/2012 15:12

Dave I wish this was all time high bought these about 10 years ago at around £3 I think they peaked just shy of £4 should have sold then. Holding since hoping they would come good one day. Only needs one good IPO and asset value will fly.

[davebowler] 24/9/2012 16:35

All time high-
Friday 21 Sep NAV Ex Income 243.95

[davebowler] 28/6/2012 13:23

All time high.

[davebowler] 01/6/2012 16:39

NAV Thursday 31 May Ex Income 221.32

[davebowler] 09/5/2012 15:55

NAV Tuesday 08 May Excluding Income 216.05

[davebowler] 27/4/2012 10:27

Portfolio Update



The Board of International Biotechnology Trust plc (the "Company") notes that today a definitive agreement has been signed by Jazz Pharmaceuticals (NASDAQ:JAZZ) to buy the unquoted portfolio company EUSA Pharma for $650m in cash plus a potential $50m milestones payment.



The Director's have changed the valuation of the Company's interest in EUSA Pharma by £1.9m from £2.7m to £4.6m on a cost of £2.4m to reflect the terms of the deal. This change in valuation will be included in the Company's Net Asset Value from today and will be released to the market on Monday. The increase to NAV per share in comparison to that released yesterday is 3.5 pence per share.



Enquiries:

Kate Bingham/David Pinniger

Telephone: [phone]

[davebowler] 16/4/2012 11:47

Edison view;
International Biotechnology Trust - Quoted portfolio continues to outperform PDF download Click for report

International Biotechnology Trust's (IBT) quoted portfolio has, for the past three years, outperformed the NASDAQ Biotechnology Index. Although the unquoted portfolio (c 16%) has been a drag on overall performance, it is reaching maturity and may provide uplifts on exit, as reflected in the 2011 sale of Cadent to Align Technologies at 3.1x the carrying book value. The manager reports that exit conditions have improved significantly during the past six months, and currently expects five to six actions per year for the next two years, with further events in 2014/15.

IBT aims to achieve long-term capital growth by investing in development stage biotechnology and other life sciences companies, both quoted and unquoted, that have high growth potential. IBT invests in companies considered to have good prospects, experienced management and strong upside potential through the development and/or commercialisation of a product, device or enablin g technology.

[sharejock] 09/2/2012 18:44

Steadily South.

[sharejock] 06/2/2012 15:51

Steadily North.